Telomerase as a Cancer Target. Development of New Molecules
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Telomeres are the terminal part of the chromosome containing a long repetitive and noncodifying sequence that has as function protecting the chromosomes. In normal cells, telomeres lost part of such repetitive sequence in each mitosis, until telomeres reach a critical point, triggering at that time senescence and cell death. However, in most of tumor cells in each cell division a part of the telomere is lost, however the appearance of an enzyme called telomerase synthetize the segment that just has been lost, therefore conferring to tumor cells the immortality hallmark. Telomerase is significantly overexpressed in 80-95% of all malignant tumors, being present at low levels in few normal cells, mostly stem cells. Due to these characteristics, telomerase has become an attractive target for new and more effective anticancer agents. The capability of inhibiting telomerase in tumor cells should lead to telomere shortening, senescence and apoptosis. In this work, we analyze the different strategies for telomerase inhibition, either in development, preclinical or clinical stages taking into account their strong points and their caveats. We covered strategies such as nucleosides analogs, oligonucleotides, small molecule inhibitors, G-quadruplex stabilizers, immunotherapy, gene therapy, molecules that affect the telomere/ telomerase associated proteins, agents from microbial sources, among others, providing a balanced evaluation of the status of the inhibitors of this powerful target together with an analysis of the challenges ahead.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400 · cited 1×
“Since the discovery of telomerase [1], an enzyme able to elongates telomeres.”
BackgroundThe RNA Component of Human Telomerase
Feng, J., Funk, W. D., Wang, S.-S., Weinrich, S. L., Avilion, A. A., Chiu, C.-P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., et al. (1995) · Science · doi:10.1126/science.7544491 · Cited by 2,227 · cited 1×
“Feng et al reported that antisense oligonucleotides complementary to sequences within or near the human telomeric template RNA resulted in suppression of telomerase activity while antisense oligonucleotides against targets that were more distant from the telomeric template failed to inhibit the action of the ribonucle…”
BackgroundControl of telomere length by the human telomeric protein TRF1
van Steensel, B., & de Lange, T. (1997) · Nature · doi:10.1038/385740a0 · Cited by 1,219
Control of Human Telomere Length by TRF1 and TRF2
Smogorzewska, A., van Steensel, B., Bianchi, A., Oelmann, S., Schaefer, M. R., Schnapp, G., & de Lange, T. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.5.1659-1668.2000 · Cited by 768 · cited 4×
“In humans, telomeres are bound by a six-protein complex called shelterin, [10,11] comprised of TRF1 and TRF2 [12, 13, 14] which in turn recruits RAP1, TIN2, TPP1 [15].”
BackgroundInfluentialStrahl, C., & Blackburn, E. H. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.1.53 · Cited by 335 · cited 1×
“Later, different groups demonstrated that AZT inhibited telomerase and/or reduce telomerase length [26, 27].”
BackgroundIn vivo Inhibition of Lung Cancer by GRN163L: A Novel Human Telomerase Inhibitor
Dikmen, Z. G., Gellert, G. C., Jackson, S., Gryaznov, S., Tressler, R., Dogan, P., Wright, W. E., & Shay, J. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1215 · Cited by 271
Therapeutic cancer vaccines: Are we there yet?
Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00979.x · Cited by 271 · cited 1×
“Many immunotherapeutic approaches are under development, either at preclinical or clinical levels [67].”
BackgroundPersistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence
Datta, A., Bellon, M., Sinha-Datta, U., Bazarbachi, A., Lepelletier, Y., Canioni, D., Waldmann, T. A., Hermine, O., & Nicot, C. (2006) · Blood · doi:10.1182/blood-2006-01-0067 · Cited by 139
Hukezalie, K. R., Thumati, N. R., Côté, H. C. F., & Wong, J. M. Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047505 · Cited by 84
Fujiwara, T., Kagawa, S., Kishimoto, H., Endo, Y., Hioki, M., Ikeda, Y., Sakai, R., Urata, Y., Tanaka, N., & Fujiwara, T. (2006) · International Journal of Cancer · doi:10.1002/ijc.21846 · Cited by 73 · cited 1×
“Some examples are combinations with radiotherapy [96], trastuzumab [97], paclitaxel [98], doxorubicin [99], docetaxel [100] and etoposide [101].”
Background
Cited by
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., & Li, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01251-0 · Cited by 1,718
Cellular Senescence: Aging, Cancer, and Injury
Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019) · Physiological Reviews · doi:10.1152/physrev.00020.2018 · Cited by 1,270
Exploiting senescence for the treatment of cancer
Wang, L., Lankhorst, L., & Bernards, R. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00450-9 · Cited by 867
Telomeres and telomerase in oncogenesis (Review)
Trybek, T., Kowalik, A., Góźdź, S., & Kowalska, A. (2020) · Oncology Letters · doi:10.3892/ol.2020.11659 · Cited by 119
Metadata
- Authors
- Mengual Gomez, D. L., Armando, R. G., Cerrudo, C. S., Ghiringhelli, P. D., & Gomez, D. E.
- Venue
- Current Topics in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2016-06-30
- Volume
- 16
- Issue
- 22
- Pages
- 2432-2440
- ISSN
- 1568-0266 (ISSN-L)
- OpenAlex
- W2411929766
- Cited by
- 73
- References
- 10
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Telomerase as a Cancer Target. Development of New Molecules. https://app.cochat.ai/papers/10.2174/1568026616666160212122425
- The paper
- Mengual Gomez, D. L., Armando, R. G., Cerrudo, C. S., Ghiringhelli, P. D., & Gomez, D. E. (2016). Telomerase as a Cancer Target. Development of New Molecules. Current Topics in Medicinal Chemistry. https://doi.org/10.2174/1568026616666160212122425
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.